文献速递其他结缔组织病

抗黑色素瘤分化相关基因5抗体阳性皮肌炎患者的短期与长期结局

Short-term and long-term outcomes of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该回顾性研究纳入154例抗MDA5抗体阳性皮肌炎患者,26.0%在缓解诱导期死亡,呼吸衰竭为最常见死因;存活者5年累积生存率96.8%、无复发生存率77.4%,7.9%实现完全无药缓解。抗MDA5抗体滴度正常化者仅2例复发,JAKi出现后重症患者6个月生存率较前显著提高(P=0.03)。

要点

  • 154例中40例(26.0%)在缓解诱导期死亡,呼吸衰竭为最常见死因。
  • 存活者5年累积生存率96.8%、无复发生存率77.4%,7.9%实现完全无药缓解。
  • 重症患者中JAKi应用后6个月生存率较前显著提高(P=0.03)。

核心结论

  • MDA5-DM患者缓解诱导期后长期生存总体良好,但复发常见;抗MDA5抗体状态与复发相关;JAKi可能改善重症难治患者的生存。

研究设计与样本

  • 回顾性收集MDA5-DM患者的基线特征、治疗及短期和长期结局(包括生存、复发和抗MDA5抗体滴度),共纳入154例患者;进行描述性统计并比较复发与未复发患者的临床参数,同时评估使用Janus激酶抑制剂(JAKi)的短期生存。

主要发现

  • 154例中40例(26.0%)在缓解诱导期死亡,呼吸衰竭为最常见死因。
  • 缓解诱导期存活的114例中,5年累积生存率为96.8%,无复发生存率为77.4%,7.9%的患者实现完全无药缓解。
  • 54例患者抗MDA5抗体滴度正常化,其中仅2例在正常化后复发。
  • 重症患者中,JAKi治疗出现后的6个月生存率较其出现前显著提高(P=0.03)。

临床怎么用

  • 作者认为抗MDA5抗体状态与复发相关,JAKi可能改善重症难治性MDA5-DM患者的生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) is a subtype of dermatomyositis characterized by frequent interstitial lung disease and reduced muscle involvement. This study aimed to determine the short-term and long-term outcomes of patients with MDA5-DM. METHODS: Information on baseline characteristics, treatments and short-term and long-term outcomes of patients with MDA5-DM including survival, relapse and the titre of anti-MDA5 antibody, was retrospectively collected. Descriptive statistics regarding clinical outcomes were calculated, and a comparison of clinical parameters between patients with and without relapse was performed. The short-term survival according to the use of Janus kinase inhibitors (JAKi) was also assessed. RESULTS: A total of 154 patients with MDA5-DM were included in the study. Forty patients (26.0%) died during the remission induction phase, with respiratory failure being the most common cause of mortality. Among the 114 patients who survived the remission induction phase, the 5-year cumulative survival and relapse-free survival rates were 96.8% and 77.4%, respectively, and 7.9% of patients achieved complete drug-free remission. Fifty-four patients achieved normalization of anti-MDA5 antibody titres and only two of them relapsed after normalization. In the severe patients, the 6-month survival rate became significantly higher after the emergence of the JAKi treatment compared with before its existence (P = 0.03). CONCLUSION: Although relapse often occurs, the long-term survival of MDA5-DM patients who survived the remission induction phase is generally favourable. The status of the anti-MDA5 antibody is associated with relapse. JAKi may improve the survival of refractory patients with severe MDA5-DM.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ida T, Furuta S, Fujiwara M, et al. Short-term and long-term outcomes of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2025. PMID: 38216799. doi:10.1093/rheumatology/keae011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。